Pre-habilitace pacientů zařazených k transplantaci jater

Petr Píza **KARIP IKEM** 14.6.2023 XXV. Dny intenzivní medicíny Kroměříž





MOTTO: "Transplantace nabízí nemocným příležitost ke zlepšení kvality života a větší sociální nezávislost!

Transplantace není prospěšná pouze pro jednotlivce, ale představuje také hodnotu pro větší "ekonomiku zdraví". Někteří pacienti se navíc mohou vrátit do práce, a tím jsou méně závislí na státní podpoře."

"Cílem je maximalizovat roky života získané transplantací dárcovského orgánu".



Waiting List - "Kdo nečeká, není léčen!"



Prehabilitation for solid organ transplant candidates

Overview of recommendations based on the literature to discuss during the TLJ 3.0 meeting in Prague, November 13th-15th 2022.

Prehabilitace označuje proces optimalizace celkového stavu pacienta před operací s cílem zvýšit jeho schopnost odolávat zátěži operace a urychlit rekonvalescenci po operaci. Rehabilitace se zaměřuje na dosažení změn životního stylu, aby se snížilo riziko komplikací souvisejících s chirurgickým zákrokem, a měla by zahrnovat alespoň fyzický trénink, dietní režim a psychologické intervence. Cíl: udržitelný zdravý životní styl, zlepšit zdraví a kvalitu života, zlepšit klinické výsledky, např. nižší míra komplikací, kratší doba hospitalizace a <u>lepší míra přežití.</u>

PRAGUE, 13-15 NOV 2022

Randomizace mezi tréninkem a "dosavadním přístupem" již není eticky ospraveditelná, protože různé studie prokázali výhody zlepšení fyzického stavu kapacita, fyzické aktivity a stavu kosterních svalů a samotné operace.

Changes in frailty are associated with waitlist mortality in patients with cirrhosis

U pacientů s cirhózou byly změny frailty významně spojeny s úmrtím/ vyřazením ze seznamu

Pacienti s cirhózou, u kterých došlo ke <u>zlepšení stavu v průběhu času,</u> měli **nižší riziko ¥mrtí/vyřazení ze** seznamu

Data podporují longitudinální měření křehkosti u pacientů s cirhózou.

Jennifer C. Lai, Jennifer L. Dodge, Matthew R. Kappus, ..., Daniela P. Ladner, Dorry L. Segev, Elizabeth C. Verna

Muscle build-up

Muscle degradation

Zhodnocení, testování

Measurement Tools

- MELDNa Child Pugh Score
- Vital signs Echocardiogram
 - Creatinine Urinalysis
- Spirometry, Hemoglobin A1c, Colonoscopy

Global Assessment of Transplant Candidacy

Eyeball test

Objective Frailty Tool Kit

"...I know it when I see it!"

...???

ALE..., stačí motivace nemocného?

Tool	Components	Test results	Advantages and disadvantages
Fried Frailty Index	Unintentional weight loss (≥10 lbs/yr) Jamar hand grip Exhaustion Low activity level Gait speed (per 15 ft)	Frailty score ≥3 is abnormal	Has subjective, s reported compore Categorical score Limited in indivi- severe HE, ascite edema
Liver Frailty Index (LFI)	Grip strength Chair stands Balance testing	Score: <3.2 - non-frail 3.2 - <4.5 -pre- frail $\geq 4.5 - \text{frail}$	Developed for L' candidates. Performance bas continuous scale more suitable to changes over tim
The 6-minute walk test (6MWT)	Walking distance over 6 min period	> 300 m - normal $\leq 300 \text{ m} - \text{low}$ endurance < 250 m - frail	May be easily ac routine clinical c
Gait speed	Usual pace gait speed (5 meters; m/s) Use of assistive devices allowed	1 m/s is normal	Not applicable to who are wheelch
Short Physical Performance Battery Protocol (SPPB)	Gait speed balance Timed repeated chair stands	Maximum 4 points/category Score < 9 is abnormal	Quick to comple 2–3 minutes) as outpatient May be difficult in patients with 1 severe HE
Activities of daily living (ADL)	Ability to feed, toilet, dress, bathe, and transfer	Points: 3 – independent 2 – needs assistance 1 – dependent Score < 12 abnormal	Can be performe nurses It is subjective as self-reported
The Braden Scale	Physical exam and assessment of 6 criteria: skin sensory perception, moisture, activity, mobility, nutrition, and friction (ability to hold a comfortable position in a chair and bed).	Score of 23 – no risk Score of 16 – requires intervention	Can be performe nurses

selfnents. re. viduals with res, or

Т

sed, on e. May be monitor ne ccessible in care

to patients hair bound

ete (takes an

to perform moderate to

ed by

as it is

ed by

Testy ke zhodnocení frailty sy u ESLD

Frailty Index dle Friedové

Liver Frailty Index (LFI)

6-minutový test chůze (6MWT)

Test chůze (Gait)

SPPB - krátká baterie pro test fez. zdatnosti

ADL - zhodnocení aktivit denního života

Bradenova škála

Tool	Advantages in liver transplant population	Estimated time for assessment	Populations studied	Criteria for high frailty
Karnofsky Performance Score	Intuitive to clinicians and patients Applicable even to critically ill patients Low cost Fast	<pre>< 10 seconds</pre>	Inpatient Outpatient	0-40
ADLs/IADLs	Patient reported No cost Well-associated with outcomes across patient populations	3–4 minutes	Inpatient Outpatient	Difficulty with ≥2 ADLs
Liver frailty index	 Objective, performance based Applicable to outpatient setting Easy to perform 	<10 minutes	Outpatient	≥4.5
6-minute walk test	Objective, performance based Continuous scale No specialized equipment	~6 minutes	Outpatient	<250 m

Table 12.1 Select frailty measurement tools in candidates for liver transplantation

Nutrition

Lai et al. Hepatology 2017.

Muscle strength

coordination

ORIGINAL ARTICLE

Implementation of the frailty assessment to improve liver transplant outcomes

Mattia Corradi¹ · Chiara Mazzarelli² · Matteo Cesari³ · Raffaella Viganò² · Luca Saverio Belli²

Zhodnocení komplexitu křehkosti u této podskupiny pacientů: Dle Friedové anebo J.Lai et al. – – > omezení použití při sledování pacientů s OLT

"nový" FI-39 pro pacienty s OLTx

Fl se jeví jako spolehlivější než pouhé použití kritérií věku, protože poskytuje objektivní numerický parametr odrážející <u>biologický věk</u> pacienta.

AST abnormality (>40 U/L) ALT abnormality (>45 U/L) Bilirubin abnormality (> 1.0 mg/dL) Hemoglobin abnormality (<14.1 g/dL) Creatinine abnormality (> 1.17 mg/dL) Gamma-glutamyl transferase abnormality (> 50 mg/dL) Alkaline phosphatase abnormality (>129 mg/dL) Systolic blood pressure abnormality (<100 or > 140 mmHg) Diastolic blood pressure abnormality (<60 or > 90 mmHg) Muscle weakness assessed using dynamometer Obesity Need help for eating Need help for housekeeping Need help with finances Disability in transportation Balance disorders Mobility disability Memory complaints Self-reported insomnia Hearing impairment Vision impairment Tremors Osteoporosis Urinary incontinence Thyroid disease Gastrointestinal disease Renal disease Skin disease Biliary tract disease Chronic respiratory disease Cerebrovascular disease History of myocardial infarction Signs of cardiac decompensation Cardiac arrhythmias Diabetes Cancer Osteoarthritis Asthenia History/family history of neurodegenerative diseases

Method	Equipment Needed	Advantages	Disadvantages	Outcomes Studied	Summary Notes
Anthropometrics ^(142,171) (MAMC, triceps skinfold thickness) Anthropometrics (pediatric) ⁽¹⁵⁰⁾	Tape measure, skinfold thickness, calipers	Safe, rapid, bedside tool, accessible, minimal training, repeatable	Low reproducibility; affected by fluid over- load, adipose tissue loss; weak correlation with cross-sectional imaging	Concordance between DEXA and CT, post–liver transplant morbidity and mortality Comparison between MAMC and CT	Practical for large patient populations but poor accu- racy and precision; interpret with caution
BIA ⁽¹³⁵⁻¹³⁹⁾	BIA device	Safe, rapid, acces- sible, minimal to moderate training, repeatable	Strict parameters around nutritional intake and exercise before the test, positioning chal- lenging in patients with obesity	Hepatic decompensation, pretransplant mortality	Fluid retention may impact the reliability of lean body mass estimates; data using phase angle show good reliability even in patients with fluid retention
Ultrasound ^(165,172,173)	Ultrasound device	Safe, rapid, acces- sible, repeatable	Operator-dependent, challenging in patients with obesity, lack of normative data	Ultrasound of psoas com- pared with CT-based SMI, hospitalizations and mortality, severity of liver disease	More data are needed to standardize technique; able to provide echogenicity data for tissue integrity
MRI ^(134,174)	MRI machine, image analysis software	Accurate, no ra- diation, measures muscle quantity and quality	Costly, limited availability	Validated against CT imaging, acute-on- chronic liver failure and mortality	Muscle mass has been defined by fat-free muscle area
DEXA ^(142,144,145,158,175)	DEXA scanner	Safe, rapid	Radiation exposure (low),edema can limit accuracy	Mortality	Low concordance between DEXA and CT in patients with cirrhosis DEXA appendicular mass improves accuracy com- pared with CT
CT ^(131,154,157,159,160,166,169,176,177)	CT scanner, image analysis software	Accurate, rapid, measures muscle quantity and qual- ity, requires a high level of training to	Radiation exposure, not available at bedside, varying cut-points/ sites of measurement, not easily repeatable	Waitlist mortality, post- transplant mortality, decompensation, acute care use, quality of life	Has the most evidence to support its use but has challenges with radiation exposure and repeatability Muscle mass measures
CT (pediatric) ^(150-152,155,156,178)		interpret		Comparison between MAMC and CT, comparison with healthy children, motor delay, infections, hospitalizations	 that have been studied: Total psoas area Psoas muscle index SMI Total skeletal muscle attenuation

HEPATOLOGY

Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases

Jennifer C. Lai 🝺 , ¹* Puneeta Tandon, ²* William Bernal, ³ Elliot B. Tapper 🝺 , ⁴ Udeme Ekong 🝺 , ⁵ Srinivasan Dasarathy, ⁶ and Elizabeth J. Carey⁷

High visceral adiposity

Myosteatosis

Velikost a symetrie svalů Subkutánní tuková tkáň (SAT) Index tělesné hmotnosti (BMI) Procento tělesného tuku Lean Body Mass

Pouze pro výzkumné a informační účely: Intramuskulární tuková tkáň (IMAT) Index intramuskulární adipózní tkáně (IMAT) Estimated Fuel Level (EFL) Muscle Fuel Symmetry (MFS) Muscle Fuel Rating (MFR) Muscle Energy Status (MES)

18-25 y.o High Muscle Mass, Low IMAT High Muscle-Quality-BMI 22

35-50 y.o Normal Muscle Mass, Low IMAT Normal Muscle-Quality-BMI 29

CT Scan

Muscle-Sound® Ultrasound

40-50 y.o Low Muscle Mass, Low IMAT Low Muscle-Quality-BMI 17

transplantaci jater.

AGING NOTION Advancing Research and Treatment of Sarcopenia

Evropská pracovní skupina pro sarkopénii u starších lidí (EWGSOP) stanovila diagnostickou metodu sarkopenie: svalovou hmotu, svalovou sílu a

fyzickou výkonnost

doporučení: kombinované posouzení svalové hmoty a funkčního stavu (svalové síly nebo výkonnosti)

Svalovou hmotu lze kvantifikovat širokou škálou nepřímých a přímých modalit, jako je antropometrie, bioelektrická impedanční analýza (BIA), rentgenová absorpciometrie s duální energií (DEXA), ultrazvuk (US), (MRI) + (CT)

independence

AJI

	Frequency of frailty testing and clinical	Implications for
Prehabilitation program	reassessment	transplant candidacy
Daily exercise program (cumulative 150 min/week) divided into 2–3 sessions daily	12 weeks	Appropriate liver transplant candidate
Home-based or outpatient physical therapy	4–8 weeks	Proceed with liver transplantation if no further increase in frailty
Consider inpatient rehabilitation	2–4 weeks	Consider liver transplantation only if improvement in frailty
	Prehabilitation programDaily exercise program (cumulative 150 min/week) divided into 2–3 sessions dailyHome-based or outpatient physical therapyConsider inpatient rehabilitation	Prehabilitation programFrequency of frailty testing and clinical reassessmentDaily exercise program (cumulative 150 min/week) divided into 2–3 sessions daily12 weeksHome-based or outpatient physical therapy4–8 weeksConsider inpatient rehabilitation2–4 weeks

EBM

PIENTIFIC REPORTS

Home Exercise Training Improves **Exercise Capacity in Cirrhosis Patients: Role of Exercise** Adherence

ary 2018

Calvin Kruger^{1,2}, Margaret L. McNeely², Robert J. Bailey³, Milad Yavari², Juan G. Abraldes¹, Michelle Carbonneau¹, Kim Newnham¹, Vanessa DenHeyer¹, Mang Ma¹, Richard Thompson⁴, Ian Paterson⁵, Mark J. Haykowsky⁶ & Puneeta Tandon^{1,2}

С

Home-Based Exercise in Patients Awaiting Liver Transplantation: A Feasibility Study

Felicity Rhian Williams (D),^{1,5} Alice Vallance,⁵ Thomas Faulkner,⁶ Jennifer Towey,⁷ Simon Durman,⁸ Derek Kyte,^{1,3} Ahmed Mohamed Elsharkawy,^{1,4} Thamara Perera,⁴ Andrew Holt,^{1,4} James Ferguson,^{1,4} Janet M. Lord,^{1,2} and Matthew James Armstrong ^[],^{1,4}

Neexistují žádné standardizované cvičební programy, zejména domácí cvičební programy (HBEPs), pro pacienty WL-LT. Cíl: prozkoumat proveditelnost takového programu u pacientů čekajících na LT.

12 týdnů 2x týdně cvičení

ISWT - incremental shuttle walk test

SPPBT - short physical performance battery test

ADS -average daily step

<u>Domácí cvičení</u> — -> účinná metoda ke zlepšení aerobní zdatnosti u pacientů s <u>dekompenzovanou</u> cirhózou Využití **vzdáleného monitorování** způsob jak si poskytovatelé zdravotní péče mohou sledovat fyzickou aktivitu.

Home-Based Physical Activity and Diet Intervention to Improve Physical Function in Advanced Liver Disease: A Randomized Pilot Trial

Hui Wei Chen¹ · Arny Ferrando² · Michelle G. White³ · Richard A. Dennis^{2,4} · Jesse Xie³ · Margaret Pauly⁵ · Sanghee Park² · Thaddeus Bartter⁶ · Michael A. Dunn¹ · Astrid Ruiz-Margain⁷ · W. Ray Kim⁸ · Andres Duarte-Rojo^{1,3,5}

Digestive Diseases and Sciences (2020) 65:3350–3359 https://doi.org/10.1007/s10620-019-06034-2

Transplantace jater **eliminuje cirhózu NASH**, nenapraví základní etiologické/související faktory: <u>nadváhu, obezitu a diabetes</u>. Naopak velmi častý je rozvoj metabolických abnormalit a metabolického syndromu po transplantaci jater pro cirhózu související s NASH nebo jiné typy cirhózy. Obezita jeden rok po transplantaci jater 24–64 % a prevalence metabolického syndromu 50–60 %.

Transplantace jater může zhoršit kardiovaskulární faktory, jako je diabetes, obezita, hyperlipidemie a zejména hypertenze (92 % příjemců)

Sustematic Review

Therapeutic Physical Exercise Programs in the Context of NASH Cirrhosis and Liver Transplantation: A Systematic Review Marwin A. Farrugia ¹, Sebastien Le Garf ², Andrea Chierici ³, Thierry Piche ⁴, Philippe Gual ⁵,

Antonio Iannelli⁶ and Rodolphe Anty^{1,*}

32% = frekvence kardiovaskulárních příhod u příjemců 10% = úmrtí potransplantaci má kardiovaskulární příčinu

Changes in exercise frequency and cardiovascular outcomes in older adults

Kyuwoong Kim ()¹, Seulggie Choi¹, Seo Eun Hwang ()², Joung Sik Son ()², Jong-Koo Lee^{3,4}, Juhwan Oh⁴, and Sang Min Park^{1,2}*

Figure 2. Impact of the smoking status before LT on patient survival. Kaplan–Meier. (a) Cumulative

Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes

Ana Isabel López-Lazcano ¹,*^(D), Antoni Gual ¹^(D), Jordi Colmenero ²^(D), Elsa Caballería ¹, Anna Lligoña¹, Miquel Navasa², Gonzalo Crespo², Eva López² and Hugo López-Pelayo¹

Systematický přehled - vyhodnocení účinku rehabilitace fyzické kapacity a chirurgických výsledků u pacientů aktivně čekajících na WL k OLTx.

Physical Effects, Safety and Feasibility of Prehabilitation in Patients Awaiting **Orthotopic Liver Transplantation, a Systematic Review**

Wesley D. Jetten¹*[†], Rianne N. M. Hogenbirk^{2†‡}, Nico L. U. Van Meeteren^{1,3†}, Cuperus^{4†}. Joost M. Klaase^{2†} and Renate De Jono

VO2-max a skóre MELD jsou nezávislé prognostické faktory mortalita a délka hospitalizace během pre- a potransplantačního období

- — > bezpečné, proveditelné a potenciálně efektivní
- – významné zlepšení v aerobního prahu nebo fyzické kapacity při cvičení střední až vysoké intenzity
- — > významný medián rozdílu 17 dnů v délka pobytu v nemocnici mezi intervencí a kontrolou skupiny
 - ——-> dodržování programu **38–90** % (bez dozoru) a **94** % pod dohledem
 - ACCESS \mathbf{O}

BWΛ

ID Jane Doe	Hei 150	ght 5.9cm	Age 51	Gende Femal	r Test D e 2021.	0ate / Time .03.31.15:44
Body Compo	sition An	alysis	0.01			
Total Body Water(L)	27.4 (26.4 ~ 32.2)	27.4	aer Son Lea 34	.9	Pat Free Ma	ss weight
Protein (kg)	7.1 (7.0 ~ 8.6)		(33.8 ~	41.4)	37.1 (35.8 - 43.8	$(43.9 \sim 59.5)$
Minerals (kg)	$\underset{(2.44\sim2.98)}{2.64}$	non-osseous				
Body Fat Mass (kg)	$\underset{(10.3\sim16.5)}{22.0}$					
Muscle-Fat A	nalysis					
	Under	Norma	1	nie	Over	
Weight (kg)	55 70	85 100	¹¹⁵ ¹³⁰	145	160 17	5 190 205 🦮
SMM Skeletal Muscle Mass (kg)	70 80	90 100 — 19.5	110 120	130	140 150	o 160 170 [%]
Body Fat Mass (kg)	40 60	80 100	160 220	22.0	340 400	0 460 520 [%]
Obesity Anal	ysis					
	Under	Norma	1		Over	
BMI (kg/m ²)	10.0 15.0	18.5 22.0	25 .0 30.0 24.0	35.0	40.0 45.1	0 50.0 55.0
PBF (%) Percent Body Fat	8.0 13.0	18.0 23.0	28.0 33.0	38.0 37	43.0 48.0 .2	0 53.0 58.0
Segmental Lo	ean Analy	sis	Based on idea	l weight 🚥	Based or	n current weight
	Under	Norma	l i	Over	6	ECW Ratio
Right Arm (kg) (%)	55 70	85 100	115 130 2.00 01.2	145	160 175	0.378
Left Arm (kg) (%)	55 70	85 100 1.	115 130 91	145	160 175	0.378
Trunk (kg)	70 80	90 100	110 120 7.7	130	140 150	0.398
Right Leg (kg)	70 80	90 100 5.24	110 120	130	140 150	0.403
Left Leg (kg) (%)	70 80	90 100 5.15	110 120	130	140 150	0.404
ECW Ratio A	nalvsis					
	Under	Norma	1		Over	
ECW Ratio	0.320 0.340	0.360 0.380	0.390 0.40	0 0.410 .398	0.420 0.43	10 0.440 0.450
Body Compo	sition His	tory				
Weight (kg)	65.3 63	.9 62.4	61.8	62.3	60.9	60.5 59.1
SMM Skeletal Muscle Mass (kg)	20.1 20	0.0 19.7	19.7	19.8	19.7	19.8 19.5
PBF (%)	41.3 40	.7 39.2	39.0	39.4	38.6	37.7 37.2
ECW Ratio	0.399 0.3	0.390	5 0.396	0.397	0.396	0.398 0.398
⊠Recent ⊡Total	20.07.21 20.0 15:11 14	8.27 20.09.20 58 15:02	0 20.11.23 15:23	20.12.21 15:00	21.02.19 14:52	21.03.20 15:12 21.03.31 15:44

[BWA 2.0]

InBody

www.inbody.com

InBody Score $67/100 \, { m Points}$

Total score that reflects the evaluation of body composition. A muscular person may score over 100 points.

Visceral Fat Area

200					
150			116.8		
100					
50					
	-	-	60	80	
	20	40	60	80	Aye

Target Weight	51.7 kg
Weight Control	-7.4 kg
Fat Control	- 10.1 kg
Muscle Control	+ 2.7 kg

Research Parameters Intracellular Water 16.5 L (16.3~19.9)

	* ***** **	(1000 1707)
Extracellular Water	10.9 L	(10.0~12.2)
Basal Metabolic Rate	1171 kc	al (1255~1451)
Waist-Hip Ratio	0.94	(0.75~0.85)
Body Cell Mass	23.6 kg	(23.4~28.6)
SMI	5.8 kg	/m²

Whole Body Phase Angle 4.0° φ(°)50 kHz

2000

•3000 kHz

Y

Z(Ω) RA LA TR RL LL TR [Clamp Type, Lying Posture] [000/000/000]

Copyright@1996- by InBody Co., Ltd. All rights reserved. BR-English-C7-B-140208

- A -

Cario-Respiratory-Fitness (CRF) - 2.0

splendohealth

	4:31	🗢 🗖	4:31	
Connect Fitness Tracker	exampleadmin	Settings		Community
	Today's Activity Updated 6 months ago. Open the FitBit latest data from your device.	app to sync the	Follow other videos and	r participants as they complete log exercise!
12:45 NON 27 9 76	 Asleep (29%) Lying Down (4%) Not Active (64%) Very Lightly Active (2%) Lightly Active (1%) Moderately Active (0%) Vigorously Active (0%) 		Macabu started using th a day ago	ne EL-FIT app to track progre
	Daily Steps Click or swipe over the chart to see step	counts.	Trainer 2 just exceeded t steps today! 2 days ago	he daily step goal with 7,953
instructions that came with your physical tracker to install the FitBit app, create a account and pair your fitness tracker.	- Goal: 2,50	00 steps per day	Trainer 2 was awarded a active for more 3 days ago	Heart badge for being than 30 minutes!
nstructions that came with your physical tracker to install the FitBit app, create a account and pair your fitness tracker.	– Goal: 2,50	00 steps per day	Trainer 2 was awarded a active for more 3 days ago	Heart badge for being than 30 minutes!
structions that came with your physical acker to install the FitBit app, create a ccount and pair your fitness tracker. Link FitBit Account	– Goal: 2,50 Total Steps (All Time)	00 steps per day 98,417	Trainer 2 was awarded a active for more 3 days ago Trainer 2	Heart badge for being than 30 minutes!
structions that came with your physical racker to install the FitBit app, create a ccount and pair your fitness tracker. Link FitBit Account	Total Steps (All Time) Average Steps (Last 2 Weeks)	98,417 6,562	Trainer 2 was awarded a active for more 3 days ago Trainer 2 just exceeded t steps today!	Heart badge for being than 30 minutes! (6) 1 he daily step goal with 8,841
Instructions that came with your physical racker to install the FitBit app, create a account and pair your fitness tracker.	Total Steps (All Time) Average Steps (Last 2 Weeks) Videos Watched (All Time)	98,417 6,562 0	Trainer 2 was awarded a active for more 3 days ago Trainer 2 just exceeded t steps today! 4 days ago	Heart badge for being than 30 minutes! (© 1) he daily step goal with 8,841
An extractions that came with your physical aracker to install the FitBit app, create a account and pair your fitness tracker.	Total Steps (All Time) Average Steps (Last 2 Weeks) Videos Watched (All Time) Videos Watched (I ast 2 Weeks)	98,417 6,562 0	Trainer 2 was awarded a active for more 3 days ago Trainer 2 just exceeded t steps today! 4 days ago	Heart badge for being than 30 minutes! (© 1) he daily step goal with 8,841

Balance & Miscellaneous

4 Exercise Videos

Available to Low & Moderate Intensity

Practical prehabilitation program

- UPMC LTx nutrition and prehabilitation guidelines
 - Standardize candidates nutritional status evaluation and monitoring
 - Home-health exercise program
 - Take advantage of
 - ELFIT

? -

- Research program (SarcoFit 2.0 Lab)
- Sarcopenia and Fitness studies

Závěr (doporučení, guidelines) HEPATOLOGY

Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases

Jennifer C. Lai D,¹* Puneeta Tan and Elizabeth J. Carey⁷

Jennifer C. Lai D,¹* Puneeta Tandon,²* William Bernal,³ Elliot B. Tapper D,⁴ Udeme Ekong D,⁵ Srinivasan Dasarathy,⁶

Patient with cirrhosis	Primary prevention	Secondary prevention	Tertiary prevention	Prevent the occurence of undesirable health outcomes
Aim	- Prevent development - Delay onset	 Early diagnosis Prompt initiation of treatment Slow progression 	- Rehabilitate - Reverse	
Assessment	- Malnutrition screening - Assessment of muscle dysfunction	 Evaluate for etiologic risk factors Explore dietary preferences and barriers to exercise 	- Reassess for progression of malnutrition, frailty, and/or sarcopenia despite primary and secondary preventative efforts	
		Diagnostic toolbox		
Action	 Educate patients and caregivers Encourage positive health behaviors Empower patients with specific skills 	 Apply management toolbox Co-management with a registered dietician and certified exercise physiologist/physical therapist, if available 	 Refer to a registered dietician, certified exercise physiologist/physical therapist, and/or health behavior specialist for co-management Consider center-based rehabilitation, intensive nutritional supplementation 	
		Management toolbox		

Patient with cirrhosis	Primary prevention	Secondary prevention	Tertiary prevention	Prevent the occurence of undesirable health outcomes
Aim	 Prevent development Delay onset 	 Early diagnosis Prompt initiation of treatment Slow progression 	- Rehabilitate - Reverse	
Assessment	- Malnutrition screening - Assessment of muscle dysfunction	 Evaluate for etiologic risk factors Explore dietary preferences and barriers to exercise 	- Reassess for progression of malnutrition, frailty, and/or sarcopenia despite primary and secondary preventative efforts	
		Diagnostic toolbox		
Action	 Educate patients and caregivers Encourage positive health behaviors Empower patients with specific skills 	 Apply management toolbox Co-management with a registered dietician and certified exercise physiologist/physical therapist, if available 	 Refer to a registered dietician, certified exercise physiologist/physical therapist, and/or health behavior specialist for co-management Consider center-based rehabilitation, intensive nutritional supplementation 	
		Management toolbox		

FIG. 2. The three levels of disease prevention and health promotion as applied to management of malnutrition, frailty, and sarcopenia in patients with cirrhosis.

.

Diagnostic Toolbox

Select tools based on the clinical scenario

Otázky a výzkumné záměry: - impakt frailty na mortalitu po Tx - longitudinální vývoj změn frailty na outcome - vztah mezi progresí org. selhání a frailty

Pracovní skupina pro frailty v Tx (multioborová spolupráce):

projekty, navýšení financování implementace EBM měření, standard péče intervence (sv.hmota, sv.funkce, aktivita, nutrice) — — > pre-rehabilitační programy

2019

ne-fyzické aspekty frailty (kognitivní, emocionální, sociální, environmentální) nem.doporučení národní guidelines výzkum

...děkuji za pozornost

petr.piza@ikem.cz

